Valneva Announces Closing of Upsized €102.9 Million Global Offering
04 Octobre 2022 - 10:00PM
- The financing was led by US healthcare specialist Deep
Track Capital and also
included existing
shareholders such as French state-owned bank
Bpifrance
- Proceeds to be primarily used to
continue to advance both the Company’s Phase 3 Lyme disease and
chikungunya vaccine candidates towards marketing
approval and to progress
preclinical assets
Saint Herblain (France), October 4, 2022 –
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a
specialty vaccine company, announced today the closing of its
previously announced global offering to specified categories of
investors of an aggregate 21,000,000 new ordinary shares,
consisting of a public offering of 375,000 American Depositary
Shares (“ADSs”), each representing two ordinary shares, in the
United States at an offering price of $9.51 per ADS (the “U.S.
Offering”), and a concurrent private placement of 20,250,000
ordinary shares in Europe (including France) and other countries
outside of the United States at the corresponding offering price of
€4.90 per ordinary share (the “European Private Placement”, and,
together with the U.S. Offering, the “Global Offering”). Aggregate
gross proceeds of the Global Offering, before deducting
underwriting commissions and estimated expenses payable by the
Company, were approximately €102.9 million ($99.9 million).
Valneva’s ordinary shares are listed on Euronext
Paris under the symbol “VLA” and its ADSs are listed on the Nasdaq
Global Select Market under the symbol “VALN”.
Goldman Sachs, Jefferies, Guggenheim Securities
and Bryan, Garnier & Co. acted as joint bookrunners for the
Global Offering.
The Company has filed a shelf registration
statement on Form F-3 relating to the ADSs and ordinary shares sold
in the Global Offering with the U.S. Securities and Exchange
Commission (“SEC”) on August 12, 2022, which was declared effective
on August 19, 2022. The offering was made by means of a prospectus
and copies of the prospectus relating to and describing the terms
of the Global Offering may be obtained from Goldman Sachs & Co.
LLC, Attn: Prospectus Department, 200 West Street, New York, New
York 10282, telephone: 866-471-2526, facsimile: 212-902-9316,
e-mail: prospectus-ny@ny.email.gs.com or Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at +1 877 821 7388 or by
email at Prospectus_Department@Jefferies.com.
Application was made to list the new ordinary
shares issued pursuant to the Global Offering on Euronext Paris
pursuant to a listing prospectus (the “Listing Prospectus”) which
was approved by the Autorité des Marchés Financiers (“AMF”) on
September 30, 2022 under number 22-405. The Listing Prospectus
comprises (i) the 2021 universal registration document filed with
the AMF on March 23, 2022 (document d’enregistrement universel
2021) under number D. 22-0140 (the “2021 URD”), as completed by an
amendment to the 2021 universal registration document filed with
the AMF on September 30, 2022 under number D. 22-0140-A01 (the
“Amendment”) and (ii) a securities note (Note d’opération) (the
“Securities Note”), including (iii) a summary of the prospectus.
Copies of the Company’s 2021 URD, as amended, is available free of
charge on the Company’s website. The Listing Prospectus has been
published on the Company’s website and on the AMF’s website
(www.amf-france.org).
About Valneva SE
Valneva is a specialty vaccine company focused
on the development and commercialization of prophylactic vaccines
for infectious diseases with significant unmet medical need. The
Company takes a highly specialized and targeted approach to vaccine
development and then applies its deep understanding of vaccine
science to develop prophylactic vaccines addressing these diseases.
Valneva has leveraged its expertise and capabilities both to
successfully commercialize three vaccines and to rapidly advance a
broad range of vaccine candidates into the clinic, including
candidates against Lyme disease and the chikungunya virus.
Media
& Investor ContactsLaëtitia Bachelot-FontaineVP Global
Communications & European Investor RelationsM +33 (0)6 4516
7099
laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
|
|
Disclaimer
This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities in any
jurisdiction, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of that jurisdiction. The registration statement
can be accessed by the public on the website of the SEC.
This announcement is an advertisement and not a
prospectus within the meaning of Regulation (EU) 2017/1129 of the
European Parliament and of the Council of 14 June 2017, as amended
(the “Prospectus Regulation”).
In France, the European Private Placement
described above took place solely as a placement to the benefit of
categories of persons, in accordance with Article L. 225-138 of the
“Code de commerce” and applicable regulations. The European Private
Placement is reserved, in Europe (including in France), to
“qualified investors”, as that term is defined in Article 2(e) of
the Prospectus Regulation.
In relation to each member state of the European
Economic Area other than France (each, a “Relevant Member State”),
an offer of the securities referred to herein was made and will not
be made to the public in that Relevant Member State, other than:
(i) to any legal entity which is a qualified investor as defined in
the Prospectus Regulation; (ii) to fewer than 150 natural or legal
persons per relevant member state; or (iii) in any other
circumstances falling within Article 1(4) of the Prospectus
Regulation; provided that no such offer of the securities referred
to herein shall require the Company to publish a prospectus
pursuant to Article 3 of the Prospectus Regulation. For the
purposes of the above, the expression an “offer to the public” in
any Relevant Member State shall have the meaning ascribed to it in
article 2(d) of the Prospectus Regulation.
This communication is being distributed only to,
and is directed only at (a) persons outside the United Kingdom, (b)
persons who have professional experience in matters relating to
investments falling within Article 19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”), and (c) high net worth entities, and other persons to
whom it may otherwise lawfully be communicated, falling within
Article 49(2) of the Order (all such persons together being
referred to as “relevant persons”). Any investment or investment
activity to which this communication relates is available only to
relevant persons and will be engaged in only with relevant persons.
Any person who is not a relevant person should not act or rely on
this communication or any of its contents.
This press release has been prepared in both
French and English. In the event of any differences between the two
texts, the French language version shall supersede.
- 2022_10_04_Verona_Closing_PR_EN_Final
Valneva (EU:VLA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Valneva (EU:VLA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024